Table 1.

Patient characteristics

	All patients n = 271		Operated patients n = 139		Patients treated with calcimimetics n = 48		Patients without active treatment n = 84
Age (years)	62 ± 12 (29–86)*		60 ± 11 (29–81)*		67 ± 11 (43–86)*		64 ± 11 (31–83)*
Sex (n)
Female	205 (76%)		107 (77%)		34 (71%)		64 (76%)
Male	66 (24%)		32 (23%)		14 (29%)		20 (24%)
PTH (pmol/L) (normal range 1.3–6.8 pmol/L)	16.1 ± 11.3 (2.4–121.9)*	n = 271	17.9 ± 13.5 (4.5–121.9)*	n = 139	16.7 ± 11.2 (4.3–57.1)*	n = 48	12.6 ± 5.1 (2.4–26.0)*	n = 84
Serum calcium (mmol/L) (normal range 2.10–2.50 mmol/L)	2.66 ± 0.21 (2.11–3.86)*	n = 271	2.72 ± 0.21 (2.11–3.86)*	n = 139	2.67 ± 0.20 (2.14–3.14)*	n = 48	2.56 ± 0.18 (2.16–2.96)*	n = 84
Serum phosphate (mmol/L) (normal range 0.7–1.4 mmol/L)	0.9 ± 0.2 (0.3–1.5)*	n = 223	0.8 ± 0.2 (0.3–1.2)*	n = 120	0.9 ± 0.2 (0.6–1.2)*	n = 38	0.9 ± 0.2 (0.5–1.5)*	n = 65
24-h urinary calcium (mmol/24 h) (normal range 2.5–7.5 mmol/24 h)	7.2 ± 4.0 (0.1–18.5)*	n = 198	8.8 ± 3.9 (0.1–18.5)*	n = 99	6.4 ± 3.5 (0.7–14.3)*	n = 37	5.6 ± 3.8 (0.5–17.5)*	n = 62
SUVmax (early images)	6.1 ± 2.9 (1.5–20.5)*	n = 197	6.3 ± 2.7 (1.5–12.7)*	n = 127	5.9 ± 2.6 (2.7–12.5)*	n = 36	5.7 ± 3.8 (2.1–20.5)*	n = 34
SUVmax (late images)	4.9 ± 2.2 (1.3–13.7)*	n = 203	5.0 ± 2.2 (1.3–12.0)*	n = 132	4.7 ± 2.4 (1.6–13.7)*	n = 37	4.4 ± 2.0 (1.8–9.9)*	n = 34

PTH parathyroid hormone, SUV_max maximum standardized uptake value

*mean ± SD (range)